ALFA Finder| Margins | Shifting toward higher-margin FDF and regulated market exports. |
|---|---|
| Demand visibility | Strong visibility in Anaesthetic and Anti-diabetic chronic segments. |
| Management confidence | High focus on technical capabilities and global expansion strategy. |
Growth
Infrastructure capacity includes 1 billion tablets and capsules, targeting 40 million injection vials for high-value injectable segments.
Outlook
EU GMP certification scheduled for Q2 2026; targeting scale-up of 15+ pipeline products across diverse therapeutic categories.
Risks
Heavy dependence on R&D pipeline conversion and successful commercialization of patent-pending formulations.
Last quarter's promises, checked
Delivered
- Guided ~20% Revenue growth → delivered 18.9% (= BEAT)
- Guided 33%-35% EBITDA margin → delivered 35.5% (= BEAT)
- Guided INR 30-35cr DSM revenue → delivered INR 30-35cr (= BEAT)
Partly delivered
- Guided Contrast Media launch Q4 FY26 → delayed to H2 FY27 (= PARTIAL)
- Guided US/EU audit for Ambernath → pending auditor availability (= PARTIAL)
Missed
- Guided Q4 revenue impact INR 0 → delivered INR 10cr loss due to headwinds (= MISS)
Earnings Call Transcript filed with NSE, NSE: SUPRIYA. Summary written with AI assistance from the document.
Supriya Lifescience Ltd: key numbers
- Share price
- ₹632.10
- Market cap
- ₹5,087 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 28.7×Sector 43.7×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Ltd
All →Supriya Lifescience Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹206 Cr (+3.2% YoY), EBITDA ₹45 Cr (-37.5%), margin 22%. LATAM regulatory shock, Ambernath ramp-up costs and raw material inflation hit margins; FY27 margin guidance cut to 23–25%.
- Call
- Guides 20% growth
Supriya Lifescience Results Update
Supriya Lifescience's Q2 FY27 revenue rose 3.2%, but EBITDA and PAT fell sharply. Ambernath ramp-up costs and LATAM regulatory shifts hurt margins.
Supriya Lifescience Q2 FY27 Results: Net Profit ₹29.2 Cr, Down 42.1% YoY
Supriya Lifescience Ltd reported revenue from operations of ₹206.3 Cr (+3.3% YoY) and net profit of ₹29.2 Cr (-42.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29.2 Cr · -42.1% YoY
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Supriya Lifescience Board Meeting Date
Supriya Lifescience will hold a board meeting on 6 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after results are declared.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed a pending case was admitted by the Supreme Court. An interim order precludes coercive action against directors while the matter is sub judice.